Login / Signup

A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever.

Adebola Tolulope OlayinkaJosephine BournerGeorge O AkpedeJoseph OkoegualeChukwuyem AbejegahNnennaya A AjayiChristian AkudeOluwafemi AyodejiDaniel G BauschHilde de ClerckChioma Cindy Dan-NwaforJake DunningCyril Oshomah EramehJustus Ndulue EzePierre B H FormentyAnnelies GillesenSulaiman JallohMarie JaspardTolulope JegedeJacob MaikereDenis MalvyEphraim Ogbaini-EmovonOlalekan Ezekial OjoSylvanus OkogbeninKwame O'NeillMaria-Lauretta OrjiSampson Omagbemi OwhinMichael RamharterRobert J SamuelsNathan Yakubu ShehuLaura MersonAlex Paddy SalamNzelle Delphine KayemPeter HorbyChikwe IhekweazuPiero L Olliaro
Published in: PLoS neglected tropical diseases (2022)
This project represents the first step towards delineating the clinical development pathway for new Lassa fever therapeutics, following a period of 40 years without advancement. Future planned projects will bolster the work initiated here to continue the advancement of LF clinical research through a regionally-centred, collaborative methodology, with the aim of delineating a clear pathway through which LF clinical trials can progress efficiently and ensure sustainable investments are made in research capacity at a regional level.
Keyphrases
  • clinical trial
  • phase iii
  • quality improvement
  • open label
  • phase ii
  • double blind
  • study protocol
  • small molecule
  • current status